Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Are Wall Street Analysts Predicting Elevance Stock Will Climb or Sink?

May 22, 2026 at 08:03 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

With a market cap of $84.7 billion, Elevance Health, Inc. (ELV) is one of the largest health insurance and managed healthcare companies in the United States. Headquartered in Indianapolis, Indiana, the company provides a broad range of health benefits, pharmacy, behavioral health, and care management services to individuals, employers, government programs, and healthcare providers.

ELV stock has declined 2.6% over the past 52 weeks and has surged 11.2% on a YTD basis. In comparison, the S&P 500 Index ($SPX) has returned 27.4% over the past year and is up 8.8% in 2026.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

Narrowing the focus, ELV has also lagged behind the State Street Health Care Select Sector SPDR Fund’s (XLV) 12.6% rise over the past 52 weeks but has outpaced its 4.3% YTD drop.

On Apr. 22, Elevance released its FY2026 Q1 earnings, and its shares popped 5.5% in the next trading session as investors responded positively to the company’s stronger-than-expected underlying operating performance and improved full-year outlook. It reported adjusted diluted EPS of $12.58, comfortably exceeding Wall Street expectations, supported by disciplined cost management, favorable claims experience, and stronger investment income. Revenue for the quarter rose to $49.5 billion, driven by growth across the company’s Health Benefits and Carelon businesses.

Investor sentiment was further boosted after Elevance raised its full-year FY2026 adjusted EPS guidance to $26.75, signaling management’s growing confidence in the company’s operational performance and medical cost visibility.

For the current year ending in December, analysts expect ELV’s EPS to decrease 11.2% year over year to $26.91. Moreover, the company has surpassed or met analysts’ consensus estimates in three of the past four quarters, while missing on one occasion.

Among the 22 analysts covering the stock, the consensus rating is a “Moderate Buy.” That’s based on 14 “Strong Buy” ratings and eight “Holds.”

The current consensus is more bullish than a month ago, when it had 12 “Strong Buy” suggestions.

On May 20, Mizuho raised its price target on Elevance Health to $435 from $385 while reiterating an “Outperform” rating on the stock. The firm cited solid first-quarter results across the managed care sector and noted a lower risk of unfavorable medical loss ratio trends through the end of 2026, which supported the upward revision to its valuation outlook.

ELV currently trades above the mean price target of $387.20.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article